Search
Search Results
-
Ketamine in neuropsychiatric disorders: an update
The discovery of ketamine as a rapid-acting antidepressant led to a new era in the development of neuropsychiatric therapeutics, one characterized by...
-
Psychiatric disorders of the combination of levetiracetam either with lacosamide or perampanel: a retrospective cohort study
Background The number of patients with epilepsy receiving perampanel or lacosamide as an add-on treatment following levetiracetam treatment has...
-
-
Interaktionen zwischen anfallssupprimierenden Medikamenten und Empfehlungen für Kombinationstherapien
Pharmacotherapy is the most important pillar in the treatment of epilepsies. In approximately 50% of epilepsy patients monotherapy with anti-seizure...
-
The pharmacological treatment of epilepsy: recent advances and future perspectives
The pharmacological armamentarium against epilepsy has expanded considerably over the last three decades, and currently includes over 30 different...
-
Integrative Analyses Identify KCNJ15 as a Candidate Gene in Patients with Epilepsy
IntroductionAlthough there is accumulating evidence that genetic factors play a vital role in the pathogenesis of epilepsy, few epilepsy-associated...
-
Third-Generation Antiseizure Medication in the Treatment of Benzodiazepine-Refractory Status Epilepticus in Poststroke Epilepsy: A Retrospective Observational Register-Based Study
Background and ObjectiveStatus epilepticus in poststroke epilepsy is a challenging condition because of multiple vascular comorbidities and the...
-
Efficacy and Safety of Five Broad-Spectrum Antiseizure Medications for Adjunctive Treatment of Refractory Epilepsy: A Systematic Review and Network Meta-analysis
BackgroundOverall, up to one-third of epilepsy patients have drug-resistant epilepsy. However, there was previously no meta-analysis to support the...
-
Fluid markers of synapse degeneration in synucleinopathies
The abnormal accumulation of α-synuclein in the brain is a common feature of Parkinson’s disease (PD), PD dementia (PDD), dementia with Lewy bodies...
-
Proteomic identification of select protein variants of the SNARE interactome associated with cognitive reserve in a large community sample
Age-related neuropathologies progressively impair cognitive abilities by damaging synaptic function. We aimed to identify key components within the...
-
-
-
Levetiracetam for the treatment of mild cognitive impairment in Parkinson’s disease: a double-blind controlled proof-of-concept trial protocol
BackgroundMild memory impairment, termed amnestic mild cognitive impairment (aMCI), is associated with rapid progression towards dementia in...
-
A deep learning model for generating [18F]FDG PET Images from early-phase [18F]Florbetapir and [18F]Flutemetamol PET images
IntroductionAmyloid-β (Aβ) plaques is a significant hallmark of Alzheimer's disease (AD), detectable via amyloid-PET imaging. The...
-
Rapidity of CNS Effect on Photoparoxysmal Response for Brivaracetam vs. Levetiracetam: A Randomized, Double-blind, Crossover Trial in Photosensitive Epilepsy Patients
IntroductionBoth levetiracetam (LEV) and brivaracetam (BRV) eliminate the electroencephalogram photoparoxysmal response (PPR) in the human phase IIa...
-
Alzheimer-Erkrankung – welche Substanzen befinden sich derzeit in Phase-III-Studien?
BackgroundThe recent approval of aduhelm/aducanumab by the US Food and Drug Administration (FDA) in June 2021 raised hopes that further substances...
-
The Pharmacology and Clinical Efficacy of Antiseizure Medications: From Bromide Salts to Cenobamate and Beyond
Epilepsy is one of the most common and disabling chronic neurological disorders. Antiseizure medications (ASMs), previously referred to as...
